1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024

EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024

  • October 2015
  • -
  • Global Data
  • -
  • 62 pages

Summary

Table of Contents

Search Inside

EpiCast Report: Methicillin-Resistant Staphylococcus Aureus (MRSA) - Epidemiology Forecast to 2024

Summary

The Staphylococcus aureus bacterium, which was discovered in the 1880s, is a common cause of painful skin and soft tissue infections (SSTIs). The discovery of penicillin in 1928 allowed for the routine and successful treatment of S. aureus infections. However, in the late 1940s and throughout the 1950s, S. aureus developed resistance to penicillin. Another form of penicillin, called methicillin, was introduced to counter the increasing problem of penicillin-resistant S. aureus. However, beginning in the 1960s, some strains of S. aureus began demonstrating resistance to methicillin, resulting in what is now known as methicillin-resistant Staphylococcus aureus (MRSA), which is resistant to all beta-lactam antibiotics, including penicillin, methicillin, and amoxicillin. Thus, MRSA has evolved from a controllable nuisance into a serious public health concern.

For this analysis, GlobalData epidemiologists defined MRSA as bacterial infections caused by methicillin-resistant S. aureus. These bacteria are resistant to beta-lactam antibiotics, such as methicillin, amoxicillin, penicillin, and oxacillin. This analysis only includes hospitalized MRSA cases arising from the following infections: pneumonia, SSTIs, and BSIs. The International Classification of Diseases, Tenth Revision (ICD-10), code for MRSA infections (unspecified site) is A49.02.

In 2014, there were a total of 797,883 hospitalized incident cases of MRSA in the 7MM. GlobalData epidemiologists forecast that the hospitalized incident cases of MRSA in the 7MM will increase to 884,727 cases by 2024 at an Annual Growth Rate (AGR) of 1.09%. The number of hospitalized incident cases of MRSA in the US, France, Italy, Spain, UK, and Japan will increase, with AGRs ranging from 0.14% (Italy) to 3.54% (Japan), but will decrease in Germany, with a negative AGR of 0.19%.

Scope

- The Methicillin-Resistant Staphylococcus aureus (MRSA) EpiCast Report provides an overview of the risk factors and global trends of MRSA in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). provides an overview of the risk factors, comorbidities, and the global and historical trends for MRSA in the 7MM and includes a 10-year epidemiological forecast for the hospitalized incident cases of MRSA, segmented by sex, age, infection site (pneumonias, SSTIs, and bloodstream infections [BSIs]), and case definition (HA-MRSA and CA-MRSA), in these markets.
- The MRSA epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The MRSA EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global MRSA market.
- Quantify patient populations in the global MRSA market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for MRSA therapeutics in each of the markets covered.
- Identify the percentage of MRSA hospitalized incident cases by infection site and case definition.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Poliomyelitis - Pipeline Review, H1 2016

Poliomyelitis - Pipeline Review, H1 2016

  • $ 42 529
  • Company report
  • June 2016
  • by Global Markets Direct

Poliomyelitis - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Poliomyelitis - Pipeline Review, H1 2016’, provides an overview of the Poliomyelitis pipeline landscape. The report provides ...

Toxoplasmosis - Pipeline Review, H1 2016

Toxoplasmosis - Pipeline Review, H1 2016

  • $ 42 529
  • Company report
  • June 2016
  • by Global Markets Direct

Toxoplasmosis - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Toxoplasmosis - Pipeline Review, H1 2016’, provides an overview of the Toxoplasmosis pipeline landscape. The report provides ...

Streptococcal Pneumonia - Pipeline Review, H1 2016

Streptococcal Pneumonia - Pipeline Review, H1 2016

  • $ 42 529
  • Company report
  • June 2016
  • by Global Markets Direct

Streptococcal Pneumonia - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Streptococcal Pneumonia - Pipeline Review, H1 2016’, provides an overview of the Streptococcal Pneumonia pipeline ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.